Apotex Inc. v. Boehringer Ingelheim Pharmaceuticals, Inc.
1:24-cv-00577
Overview
Parties
Defendant
Boehringer Ingelheim Pharma GmbH & Co. KG Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Boehringer Ingelheim International GmbH Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Boehringer Ingelheim Pharmaceuticals, Inc. Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Plaintiff
Apotex Inc. Operating Company
Represented By
3 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., DE
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 6 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | European Counterpart (EP) | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9907756
Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
|
Filed: 2016-07-07
Issued: 2018-03-06
|
Active (2.5 yrs remaining)
Expires: 2029-06-07
|
|
|
US10105323
Pharmaceutical dosage form for immediate release of an indolinone derivative
|
Filed: 2017-05-09
Issued: 2018-10-23
|
Active (10.5 yrs remaining)
Expires: 2037-05-09
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
19
Dispositive
0
Granted
0
Denied
0
Pending / Review
11
Motions by Category
Key Dispositive Motions & Rulings